Developer docs
API playgroundTry for free, no card

Search company profiles

Flourish Research

Full company profile

uuid00054w8

Namestring
Flourish Research
Legal namestring
Flourish Research LLC
Company typeenum
Private
Founded yearstring
-
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersApex, United States
HQ citystring
Apex
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices31 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, Phase I-IV trials, early-phase research, oncology trials, cardiometabolic research
Industry4 codes
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
SECONDARYHLAGACAG
Clinical Trial Monitoring Support (On-site/Remote)
SECONDARYHLAGACAF
Investigator & Site Training / GCP Support
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Specialty Outpatient Facilities, Nec8093
Product category
Clinical Trial Site Network Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Services
TypeProfessional Services
Description

Flourish Research generates revenue by conducting Phase I-IV clinical trials for pharmaceutical sponsors and CROs. Services include patient recruitment, study execution, data collection, and regulatory support across their network of wholly-owned research sites.

flourishresearch.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Flourish Imaging
Description

Advanced imaging center partnership with Capitol Imaging Services, featuring GE HealthCare Omni PET scanner for oncology and CNS clinical trials

neworleanscitybusiness.com
+1 more record
Core offering1 text field

Flourish Research operates a network of 30+ wholly-owned clinical trial sites across the United States that conducts Phase I-IV clinical trials for pharmaceutical sponsors and CROs. Service offerings span in-patient and outpatient studies, dedicated early-phase/First-in-Human units, in-house PBMC processing, advanced imaging, and therapeutic specialization in cardiometabolic, oncology, neuroscience, and infectious diseases. The network provides patient recruitment, study execution, data collection, and regulatory support through standardized operations and integrated technology platforms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 97% patient retention rate at Boca Raton location for complex cardiovascular trials
+4 more records
Product overview1 text field

Flourish Research is an industry-leading wholly-owned clinical trial site network offering end-to-end clinical research solutions. The platform operates as a unified network with multiple integrated service modules including Phase I/early phase services with dedicated in-patient units, specialized PBMC processing labs, and advanced imaging services through a GE HealthCare partnership. The network provides therapeutic specializations in cardiometabolic, oncology, neuroscience, and infectious diseases, with sites across Alabama, California, Florida, Georgia, Illinois, Louisiana, Maryland, Michigan, North Carolina, Pennsylvania, and Texas. The company has grown through strategic acquisitions including Valkyrie Clinical Trials (oncology), Merritt Island Medical Research (neuroscience), AMC Research (Alzheimer's), and Diablo Clinical Research (infectious disease).

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Flourish Research partnered with Capitol Imaging Services to launch Flourish Imaging, an advanced imaging center in Gainesville, Georgia. The facility features a GE HealthCare Omni PET scanner supporting both clinical research and community diagnostic imaging with focus on oncology and central nervous system trials. Companies anticipate broader expansion across the Southeast.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

In February 2025, Flourish Research LLC acquired Diablo Clinical Research LLC to expand its geographic and therapeutic scope in the infectious disease clinical trials sector.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquired in June 2023, AMC Research in Charlotte, North Carolina specializes in Alzheimer's Disease research, enhancing Flourish's neuroscience research capabilities and market reach.

4Central Research Associates (CRA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquired in June 2023, Central Research Associates in Birmingham, Alabama is a multi-therapeutic site that enhances Flourish's research capabilities and provides access to new markets.

nms-capital.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquired in December 2023, MIMR is a neuroscience clinical research site in Florida that continues its leadership roles while benefiting from Flourish's growth support and expanded research capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Acquired in May 2025, CARE is a healthcare research facility in Gainesville, GA that has conducted over 150 clinical trials. The acquisition expands Flourish's geographic footprint in the Southeast and strengthens pharmaceutical client relationships.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

In 2025, Valkyrie Clinical Trials joined the Flourish Research family, bringing deep oncology experience with three locations across Southern California (Century City, Panorama City, and Murrieta). Specializes in early-phase oncology trials and high-risk immunotherapy monitoring with ICU access.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Flourish Research North Miami partners with the Center for Haitian Studies, a trusted community resource since 1989, to serve underrepresented populations in research and reduce health disparities.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Velocity is a leading integrated site organization also built via the roll-up of wholly-owned clinical trial sites across the U.S., offering Phase II-IV trials to pharma sponsors. It is the closest direct competitor to Flourish's network model, therapeutic-area breadth, and acquisition-driven growth strategy.

TypeDirect peer
Description

CenExel operates a network of wholly-owned clinical research sites specializing in early-phase and CNS trials, including in-patient units similar to Flourish's. It is a direct peer in therapeutic-area focus (neuroscience, cardiometabolic) and early-phase infrastructure.

3Accelerated Enrollment Solutions (AES) / PPD
TypeDirect peer
Description

AES was PPD's dedicated site network for patient enrollment and is the site-network business where Flourish CEO Reinhold Schulz previously served as VP Global Site Network. It remains a direct competitor in dedicated site solutions for pharma sponsors.

TypeBroad incumbent
Description

WCG is a clinical trial services company offering central IRB, technology, and site-support services to sponsors and CROs. As a broader incumbent in the clinical trial services stack, WCG competes for sponsor relationships and is the destination of Flourish's former CFO.

TypeBroad incumbent
Description

IQVIA is the largest CRO globally with embedded site networks, technology platforms, and real-world data capabilities. As a broad incumbent, it competes with Flourish both directly (own site footprint) and indirectly (full-service CRO bundling).

TypeBroad incumbent
Description

ICON is one of the largest global CROs offering full-service clinical development including site management. It competes for the same pharmaceutical sponsor contracts and can bundle site services as part of larger CRO engagements.

TypeBroad incumbent
Description

Medpace is a mid-to-large full-service CRO with embedded site operations that competes for pharmaceutical sponsor trial execution work. Its therapeutically-focused operating model is conceptually adjacent to Flourish's specialist-site positioning.

TypeBroad incumbent
Description

Syneos Health is a large CRO/SMO combination (now owned by Elliott/Veritas/Patient Square) that offers both full-service CRO and dedicated site solutions. It is a broad incumbent competitor with a wholly-owned site network similar to Flourish's.

TypeBroad incumbent
Description

PPD, now part of Thermo Fisher, is a top-3 global CRO offering full-service clinical development with embedded site management. It directly overlaps with Flourish on sponsor relationships and site network services.

TypeEmerging player
Description

Worldwide Clinical Trials is a mid-size CRO with focused therapeutic expertise (including neuroscience and cardiometabolic) that competes with Flourish on mid-sized pharma trial execution. It is a smaller-scale peer to the top global CROs but a meaningful emerging competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Flourish Research

Clinical Trial Site Network Servicesflourishresearch.com

Flourish Research firmographics

Firmographics
Name
Flourish Research
Legal name
Flourish Research LLC
Website
https://flourishresearch.com
Company type
Private
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Flourish Research industry classification

Industry
Product category
Clinical Trial Site Network Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Specialty Outpatient Facilities, Nec (8093)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
SECONDARYHLAGACAG
Clinical Trial Monitoring Support (On-site/Remote)
SECONDARYHLAGACAF
Investigator & Site Training / GCP Support

Keywords

  • Clinical trial services
  • Phase I-IV trials
  • Early-phase research
  • Oncology trials
  • Cardiometabolic research

Where Flourish Research is headquartered

Location

Headquarters

HQ city
Apex
HQ country
United States
HQ region
North America

Offices31 records

Markets served

Flourish Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Trial Services: Flourish Research generates revenue by conducting Phase I-IV clinical trials for pharmaceutical sponsors and CROs. Services include patient recruitment, study execution, data collection, and regulatory support across their network of wholly-owned research sites.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Flourish Research product offering

Product offering

Core offering

Flourish Research operates a network of 30+ wholly-owned clinical trial sites across the United States that conducts Phase I-IV clinical trials for pharmaceutical sponsors and CROs. Service offerings span in-patient and outpatient studies, dedicated early-phase/First-in-Human units, in-house PBMC processing, advanced imaging, and therapeutic specialization in cardiometabolic, oncology, neuroscience, and infectious diseases. The network provides patient recruitment, study execution, data collection, and regulatory support through standardized operations and integrated technology platforms.

Product overview

Flourish Research is an industry-leading wholly-owned clinical trial site network offering end-to-end clinical research solutions. The platform operates as a unified network with multiple integrated service modules including Phase I/early phase services with dedicated in-patient units, specialized PBMC processing labs, and advanced imaging services through a GE HealthCare partnership. The network provides therapeutic specializations in cardiometabolic, oncology, neuroscience, and infectious diseases, with sites across Alabama, California, Florida, Georgia, Illinois, Louisiana, Maryland, Michigan, North Carolina, Pennsylvania, and Texas. The company has grown through strategic acquisitions including Valkyrie Clinical Trials (oncology), Merritt Island Medical Research (neuroscience), AMC Research (Alzheimer's), and Diablo Clinical Research (infectious disease).

Differentiator

Problem solved

Functional benefit

Brands

  • Flourish Imaging: Advanced imaging center partnership with Capitol Imaging Services, featuring GE HealthCare Omni PET scanner for oncology and CNS clinical trials
  • Valkyrie

Quantifiable outcome

  • 97% patient retention rate at Boca Raton location for complex cardiovascular trials
  • +4 more outcomes

Companies that use Flourish Research

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Flourish Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Flourish Research partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Capitol Imaging ServicescoreStrategic or Co-development Partner · 29 April 2026Flourish Research partnered with Capitol Imaging Services to launch Flourish Imaging, an advanced imaging center in Gainesville, Georgia. The facility features a GE HealthCare Omni PET scanner supporting both clinical research and community diagnostic imaging with focus on oncology and central nervous system trials. Companies anticipate broader expansion across the Southeast.
  • Diablo Clinical ResearchminorStrategic or Co-development PartnerIn February 2025, Flourish Research LLC acquired Diablo Clinical Research LLC to expand its geographic and therapeutic scope in the infectious disease clinical trials sector.
  • AMC ResearchcoreStrategic or Co-development PartnerAcquired in June 2023, AMC Research in Charlotte, North Carolina specializes in Alzheimer's Disease research, enhancing Flourish's neuroscience research capabilities and market reach.
  • Central Research Associates (CRA)coreStrategic or Co-development PartnerAcquired in June 2023, Central Research Associates in Birmingham, Alabama is a multi-therapeutic site that enhances Flourish's research capabilities and provides access to new markets.
  • Merritt Island Medical Research (MIMR)coreStrategic or Co-development PartnerAcquired in December 2023, MIMR is a neuroscience clinical research site in Florida that continues its leadership roles while benefiting from Flourish's growth support and expanded research capabilities.
  • Center for Advanced Research & Education (CARE)coreStrategic or Co-development PartnerAcquired in May 2025, CARE is a healthcare research facility in Gainesville, GA that has conducted over 150 clinical trials. The acquisition expands Flourish's geographic footprint in the Southeast and strengthens pharmaceutical client relationships.
  • Valkyrie Clinical TrialscoreStrategic or Co-development PartnerIn 2025, Valkyrie Clinical Trials joined the Flourish Research family, bringing deep oncology experience with three locations across Southern California (Century City, Panorama City, and Murrieta). Specializes in early-phase oncology trials and high-risk immunotherapy monitoring with ICU access.
  • Center for Haitian StudiesminorStrategic or Co-development PartnerFlourish Research North Miami partners with the Center for Haitian Studies, a trusted community resource since 1989, to serve underrepresented populations in research and reduce health disparities.

Scale indicators10 records

Recent moves4 records

Expansion highlights6 records

Flourish Research competitors and assessment

Company assessment

Direct peers

  • Velocity Clinical Research: Velocity is a leading integrated site organization also built via the roll-up of wholly-owned clinical trial sites across the U.S., offering Phase II-IV trials to pharma sponsors. It is the closest direct competitor to Flourish's network model, therapeutic-area breadth, and acquisition-driven growth strategy.
  • CenExel Clinical Research: CenExel operates a network of wholly-owned clinical research sites specializing in early-phase and CNS trials, including in-patient units similar to Flourish's. It is a direct peer in therapeutic-area focus (neuroscience, cardiometabolic) and early-phase infrastructure.
  • Accelerated Enrollment Solutions (AES) / PPD: AES was PPD's dedicated site network for patient enrollment and is the site-network business where Flourish CEO Reinhold Schulz previously served as VP Global Site Network. It remains a direct competitor in dedicated site solutions for pharma sponsors.

Broad incumbents

  • WCG (WIRB-Copernicus Group): WCG is a clinical trial services company offering central IRB, technology, and site-support services to sponsors and CROs. As a broader incumbent in the clinical trial services stack, WCG competes for sponsor relationships and is the destination of Flourish's former CFO.
  • IQVIA: IQVIA is the largest CRO globally with embedded site networks, technology platforms, and real-world data capabilities. As a broad incumbent, it competes with Flourish both directly (own site footprint) and indirectly (full-service CRO bundling).
  • ICON plc: ICON is one of the largest global CROs offering full-service clinical development including site management. It competes for the same pharmaceutical sponsor contracts and can bundle site services as part of larger CRO engagements.
  • Medpace Holdings: Medpace is a mid-to-large full-service CRO with embedded site operations that competes for pharmaceutical sponsor trial execution work. Its therapeutically-focused operating model is conceptually adjacent to Flourish's specialist-site positioning.
  • Syneos Health (now private): Syneos Health is a large CRO/SMO combination (now owned by Elliott/Veritas/Patient Square) that offers both full-service CRO and dedicated site solutions. It is a broad incumbent competitor with a wholly-owned site network similar to Flourish's.
  • PPD (Thermo Fisher Scientific): PPD, now part of Thermo Fisher, is a top-3 global CRO offering full-service clinical development with embedded site management. It directly overlaps with Flourish on sponsor relationships and site network services.

Emerging players

  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO with focused therapeutic expertise (including neuroscience and cardiometabolic) that competes with Flourish on mid-sized pharma trial execution. It is a smaller-scale peer to the top global CROs but a meaningful emerging competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Flourish Research social profiles

Digital presence

Flourish Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Flourish Research leadership team

Management profile

Number of profiles

Profiles8 records

Flourish Research subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Flourish Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Flourish Research M&A and investment

M&A and investment

M&A5 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flourish Research

What does Flourish Research do?

Flourish Research operates a network of 30+ wholly-owned clinical trial sites across the United States that conducts Phase I-IV clinical trials for pharmaceutical sponsors and CROs. Service offerings span in-patient and outpatient studies, dedicated early-phase/First-in-Human units, in-house PBMC processing, advanced imaging, and therapeutic specialization in cardiometabolic, oncology, neuroscience, and infectious diseases. The network provides patient recruitment, study execution, data collection, and regulatory support through standardized operations and integrated technology platforms.

Is Flourish Research a public or private company?

Flourish Research is a private company. It is classified as private equity controlled and is currently operating.

When was Flourish Research founded?

Flourish Research was founded in -1. It employs 501 to 1,000 people.

Where is Flourish Research based?

Flourish Research is headquartered in Apex, United States, in the North America region.

How does Flourish Research make money?

One revenue line is on record: clinical Trial Services.

Who are Flourish Research's main competitors?

Direct peers on record are Velocity Clinical Research, CenExel Clinical Research and Accelerated Enrollment Solutions (AES) / PPD. Broad incumbents are WCG (WIRB-Copernicus Group), IQVIA, ICON plc, Medpace Holdings, Syneos Health (now private) and PPD (Thermo Fisher Scientific). Worldwide Clinical Trials is listed as an emerging player.

Does Flourish Research have an API?

No public API is recorded for Flourish Research.

What industry is Flourish Research in?

Flourish Research's product category is Clinical Trial Site Network Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGACAC, Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarAssociation of Black Cardiologists Names 2026 Spirit of the Heart HonoreesThe Association of Black Cardiologists named five honorees for its 2026 Spirit of the Heart Awards, to be presented at an event on October 3, 2026, in New York City. The honorees include Dr. Anekwe E. Onwuanyi and Dr. Tiffany M. Powell-Wiley for leadership, Georgia Arrhythmia Consultants for health promotion, Flourish Research for health equity, and Merck for the Spirit of the Heart Award.PR NewswireAssociation of Black Cardiologists Names 2026 Spirit of the Heart HonoreesThe Association of Black Cardiologists named five honorees for its 2026 Spirit of the Heart Awards, including Dr. Tiffany M. Powell-Wiley, Dr. Anekwe E. Onwuanyi, Flourish Research, Merck, and Georgia Arrhythmia Consultants & Research Institute. The awards ceremony will be held on October 3, 2026, at Cipriani Wall Street in New York City.GlobeNewswireInfectious Disease Clinical Trials Research Report 2026: $21.25 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe infectious disease clinical trials market is projected to grow from $15.1 billion in 2025 to $16.13 billion in 2026, reaching $21.25 billion by 2030, driven by increased funding for vaccine development, digital trial management adoption, and AI-assisted patient recruitment. Key developments include Roche initiating a Phase 3 clinical trial for zosurabalpin targeting CRAB and Flourish Research LLC acquiring Diablo Clinical Research LLC to expand trial capabilities. While the market benefits from enhanced healthcare infrastructure and decentralized trial models, tariffs are raising costs for essential trial materials and prompting shifts toward regional infrastructure development.openPR.comTrends in Growth, Segment Analysis, and Competitive Approaches Influencing the Infectious Disease Clinical Trials MarketThe Business Research Company published a market report projecting the global infectious disease clinical trials market to reach $21.25 billion by 2030, growing at a 7.1% CAGR, driven by increased pandemic preparedness investments, AI-assisted patient recruitment, and decentralized trial models. In February 2025, Flourish Research LLC acquired Diablo Clinical Research LLC to expand its geographic and therapeutic scope in the infectious disease clinical trials sector. The report identifies key market segments, trends including adaptive trial designs and real-world evidence integration, and forecasts North America holding the largest market share while Asia-Pacific experiences the fastest growth.GlobeNewswireFlourish Research® Announces Strategic Partnership withFlourish Research announced a strategic partnership with Capitol Imaging Services ahead of launching Flourish Imaging, an advanced imaging center in Gainesville, Georgia. The facility will feature a GE HealthCare Omni PET scanner and is expected to open in coming months, expanding clinical trial imaging capabilities and community diagnostic access.YahooFlourish Research Establishes Meaningful Presence in Oncology with Strategic Investment in Valkyrie Clinical TrialsFlourish Research announced a partnership with Valkyrie Clinical Trials, an oncology-focused network, to expand access to cancer clinical trials. Valkyrie operates three Los Angeles sites serving over 200,000 cancer patients. The deal is Flourish's fifth under Genstar Capital's ownership.PR NewswireFlourish Research Establishes Meaningful Presence in Oncology with Strategic Investment in Valkyrie Clinical TrialsFlourish Research announced a strategic partnership with Valkyrie Clinical Trials, an oncology-focused clinical research network founded by Dr. David Berz in 2021. The partnership expands Flourish's therapeutic portfolio into oncology and extends its operations to three sites in Los Angeles, California, serving a network of over 200,000 cancer patients, marking the company's fifth acquisition under private equity firm Genstar Capital. Genstar Capital, which acquired Flourish in 2024, continues to support expansion of the company's national site network toward becoming a leading integrated site network in clinical research.ObjectiveibvValuation of Clinical Research Sites: What Buyers Look For in a Clinical Research Site CompanyThe article analyzes the valuation drivers and consolidation trends within the U.S. clinical research site sector, noting that strategic acquirers account for nearly 90% of M&A activity between 2021 and Q2 2025. It highlights how factors such as scale, therapeutic specialization, and operational compliance influence transaction multiples, with mid-market operators typically trading at 6x–12x EBITDA. The text lists several recent transactions involving firms like THL Partners, BayPine, and Flourish Research to illustrate this market dynamic.PR NewswireFlourish Research Continues Expansion with Acquisition of Center for Advanced Research & EducationFlourish Research acquired the Center for Advanced Research & Education (CARE), a multi-therapeutic clinical trial facility founded in 1998. The acquisition expands Flourish's geographic footprint into the Southeast region and strengthens relationships with blue-chip pharmaceutical customers. CARE has conducted over 150 clinical trials across multiple therapeutic areas.PR NewswireFlourish Research Announces Strategic Acquisition of Diablo Clinical ResearchFlourish Research acquired Diablo Clinical Research, a multi-therapeutic clinical research facility, expanding its geographic footprint and therapeutic coverage. Diablo, established in 1995, has conducted over 1,000 trials across endocrinology, cardiovascular, and metabolic areas. The acquisition is Flourish's second under Genstar Capital's ownership.